Press release
Febrile Neutropenia Clinical Trials Analysis 2025: Antimicrobial Stewardship, Novel Anti-infectives, and Immune-Boosting Strategies Aim to Reduce Mortality | DelveInsight
Febrile Neutropenia Clinical Trials Analysis
Current clinical trials are exploring long-acting G-CSF formulations, next-generation anti-infectives with activity against resistant pathogens, and immune-enhancing therapies designed to accelerate neutrophil recovery. Strategies also include optimizing antimicrobial stewardship, tailoring prophylaxis by risk stratification, and evaluating outpatient management protocols to minimize healthcare burden.
The future landscape emphasizes precision and prevention, with studies integrating biomarkers, pharmacogenomics, and patient-reported outcomes to enhance safety, reduce recovery time, and improve quality of life. As late-stage candidates advance, febrile neutropenia management is expected to shift from reactive treatment toward proactive, individualized protection.
Curious about the latest breakthroughs in febrile neutropenia treatment? Discover cutting-edge drugs and the evolving pipeline-click here to explore: https://www.delveinsight.com/report-store/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Febrile Neutropenia Pipeline Report
• DelveInsight's Febrile Neutropenia Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline drugs for Febrile Neutropenia treatment.
• The leading Febrile Neutropenia companies include Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, Bristol-Myers Squibb, and others are evaluating their lead assets to improve the Febrile Neutropenia treatment landscape.
• Key Febrile Neutropenia pipeline therapies in various stages of development include Fexuprazan, Ondansetron controlled-release, Lirentelimab, HIP 2101, Netazepide, Cendakimab, and others.
• In August 2024, Tanvex BioPharma USA announced FDA approval of NYPOZITM (filgrastim-txid), a biosimilar referencing Neupogen®, for treating chemotherapy-induced neutropenia in cancer patients.
• In June 2025, CHMP adopted a positive opinion for Vivlipeg, another Neulasta biosimilar in the EU, for reducing neutropenia duration and incidence of febrile neutropenia after cytotoxic chemotherapy.
• In January 2025, CHMP (European Medicines Agency) adopted a positive opinion recommending EU authorization of Dyrupeg, a biosimilar to Neulasta (pegfilgrastim), intended to shorten the duration of neutropenia and help prevent febrile neutropenia.
• In December 2023, the FDA approved the on-body injector (OBI) presentation of Udencya (pegfilgrastim-cbqv) biosimilar, known as Udencya Onbody, to reduce infection from febrile neutropenia in cancer patients the day after chemotherapy.
Request a sample and discover the recent breakthroughs happening in the Febrile Neutropenia pipeline landscape @ https://www.delveinsight.com/report-store/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Febrile Neutropenia Overview
Neutropenic fever is characterized by a single oral temperature of 101°F or higher, or a sustained temperature of 100.4°F or greater for at least one hour, accompanied by an absolute neutrophil count (ANC) of less than 1500 cells per microliter. Severe neutropenia is defined as an ANC below 500 cells per microliter or a projected decline to this level within the next two hours.
Febrile neutropenia is the most common and serious complication of cancer therapy, frequently occurring in patients with hematopoietic cancers or those undergoing chemotherapy. It develops when a neutropenic patient encounters an infectious pathogen. Due to their immunocompromised state, these patients have a weakened ability to fight infections. Additionally, damage to protective barriers, such as the mucosal lining of the gastrointestinal tract or sinuses, increases vulnerability to microbial invasion, further heightening the risk of infection.
Find out more about Febrile Neutropenia medication @ https://www.delveinsight.com/report-store/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Febrile Neutropenia Treatment Analysis: Drug Profile
Plinabulin: BeyondSpring Pharmaceuticals
Plinabulin is an investigational small-molecule drug belonging to a novel class of selective immunomodulating microtubule-binding agents. It has the potential to prevent chemotherapy-induced neutropenia (CIN) while also offering anticancer benefits. Unlike standard chemotherapeutic agents and conventional microtubule-binding drugs, Plinabulin operates through a distinct mechanism of action (MOA), contributing to a differentiated safety and efficacy profile.
Learn more about the novel and emerging Febrile Neutropenia pipeline therapies @ https://www.delveinsight.com/report-store/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Febrile Neutropenia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
By Molecule Type
• Peptides
• Recombinant proteins
• Small molecule
Scope of the Febrile Neutropenia Pipeline Report
• Coverage: Global
• Key Febrile Neutropenia Companies: Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, Bristol-Myers Squibb, and others.
• Key Febrile Neutropenia Pipeline Therapies: Fexuprazan, Ondansetron controlled-release, Lirentelimab, HIP 2101, Netazepide, Cendakimab, and others.
Dive deep into rich insights for drugs used for Febrile Neutropenia treatment; visit @ https://www.delveinsight.com/report-store/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Febrile Neutropenia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Febrile Neutropenia Pipeline Therapeutics
6. Febrile Neutropenia Pipeline: Late-Stage Products (Phase III)
7. Febrile Neutropenia Pipeline: Late-Stage Products (Phase III)
8. Febrile Neutropenia Pipeline: Mid-Stage Products (Phase II)
9. Febrile Neutropenia Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Febrile Neutropenia Clinical Trials Analysis 2025: Antimicrobial Stewardship, Novel Anti-infectives, and Immune-Boosting Strategies Aim to Reduce Mortality | DelveInsight here
News-ID: 4198187 • Views: …
More Releases from DelveInsight
Hereditary Angioedema Clinical Trials Analysis 2025: Novel Therapeutics, Prophyl …
DelveInsight's "Hereditary Angioedema (HAE) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline designed to prevent and manage acute HAE attacks. Despite available C1-INH replacement therapies and bradykinin receptor antagonists, patients continue to face unpredictable, sometimes life-threatening attacks, emphasizing the need for more effective and convenient treatment options.
The HAE pipeline is progressing with next-generation C1-INH formulations, oral kallikrein inhibitors, and gene-targeted therapies that aim for long-term prophylaxis. Combination…
Cutaneous Lupus Erythematosus Clinical Trials Analysis 2025: Targeted Immunomodu …
DelveInsight's "Cutaneous Lupus Erythematosus (CLE) - Clinical Trials Analysis, 2025" highlights a dynamic pipeline addressing persistent gaps in treatment for patients with lupus-specific skin manifestations. Current therapies, such as antimalarials, corticosteroids, and immunosuppressants, often provide incomplete control or cause significant side effects, fueling the push for safer, more targeted, and more durable approaches.
Clinical research is advancing with biologics that block key immune pathways such as type I interferons, BAFF, and…
Vasculitis Clinical Trials Analysis 2025: Targeted Immunotherapies, Complement I …
DelveInsight's "Vasculitis - Clinical Trials Analysis, 2025" highlights a dynamic pipeline aimed at improving remission durability and minimizing steroid dependence in this group of rare, organ-threatening autoimmune diseases. Despite existing options like rituximab and tocilizumab, relapse rates and treatment-related toxicity remain high, underscoring the need for safer, more effective therapies.
Ongoing trials are advancing next-generation B-cell-directed agents, complement pathway inhibitors, JAK/BTK inhibitors, and selective cytokine modulators. These therapies are being explored…
Advanced Gastric Carcinoma Clinical Trials Analysis 2025: Targeted Agents, Immun …
DelveInsight's "Advanced Gastric Carcinoma (AGC) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline focused on enhancing overall survival, response durability, and tolerability in patients with unresectable or metastatic disease. Despite standard chemotherapy regimens forming the backbone of treatment, prognosis remains poor, with a high proportion of patients experiencing progression, creating a pressing need for innovative therapeutic options.
The AGC pipeline is progressing with targeted therapies including HER2-directed agents,…
More Releases for Febrile
Febrile Seizures Market Business Growth and Industry Development by 2034
The Febrile Seizures Market Is Set To Grow At An Estimated CAGR Of 6.2% From 2025 To 2034, Rising From $3.2 Billion In 2024 To $5.6 Billion By 2034.
On April 10, 2025, Exactitude Consultancy., Ltd. released a research report titled "Febrile Seizures Market" This report offers a new perspective on the Febrile Seizures Market covering an extensive range of aspects including market overview, expenditure analysis, import trends, segmentation, key players,…
Febrile Seizures Market: Global Industry Analysis and Forecast (2024-2030)
Febrile Seizures Market to reach USD 1573.16 Mn at a CAGR of 4.5 percent over the forecast period
The Febrile Seizures Market was valued at USD 1156 Million in 2023, with revenue expected to grow at a CAGR of 4.5%, reaching nearly USD 1573.16 Million by 2030.
To access more details regarding this research, visit the following webpage:https://www.stellarmr.com/report/Febrile-Seizures-Market/2064
Febrile Seizures Market Scope and Research Methodology
The Febrile Seizures Market report employs an extensive research…
Febrile Seizures Market Anticipates Growth in Forecast Period 2024-2031
The "Febrile Seizures Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Acute Febrile Neutrophilic Dermatosis Market - Defending Skin Integrity with Adv …
Newark, New Castle, USA - new report, titled Acute Febrile Neutrophilic Dermatosis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Acute Febrile Neutrophilic Dermatosis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Acute Febrile Neutrophilic Dermatosis market. The report offers…
Acute Febrile Neutrophilic Dermatosis Market Insights, Forecast to 2031
Acute Febrile Neutrophilic Dermatosis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Acute Febrile Neutrophilic Dermatosis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It…
Febrile Neutropenia Market Significantly Stepping towards the Success Till 2027
Alpha-2 antiplasmin, commonly known as a plasmin inhibitor, is a glycoprotein made by the liver, kidneys, and other bodily organs. Alpha-2 Antiplasmin is a serine protease inhibitor belonging to the Serpin superfamily that is responsible for the breakdown of fibrin clots and the inhibition of fibrinolysis. Due to an increase in fibrinolysis, a lack of Alpha 2 antiplasmin causes bleeding problems. Internal bleeding is caused by a congenital lack of…
